Epizyme logo
Epizyme EPZM

Quarterly report 2022-Q2
added 08-09-2022

report update icon

Epizyme Financial Statements 2011-2025 | EPZM

Annual Financial Statements Epizyme

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

103 M 1.11 B 1.92 B 732 M 1.06 B 557 M 362 M 632 M 520 M - -

Shares

103 M 101 M 89.9 M 71.9 M 61.5 M 57.1 M 39.8 M 33 M 17 M - -

Historical Prices

1.23 10.9 20.9 10.2 16.1 10.5 9.09 19.1 30.4 - -

Net Income

-251 M -232 M -170 M -124 M -134 M -110 M -132 M -55 M -3.48 M -702 K -21 M

Revenue

37.4 M 15.8 M 23.8 M 21.7 M 10 M 8.01 M 2.56 M 41.4 M 68.5 M 45.2 M 6.94 M

Cost of Revenue

10.5 M 5.07 M - - - - - - - - -

Gross Profit

- 10.7 M - - - - - - - - -

Operating Income

-238 M -225 M -177 M -128 M -137 M -112 M -133 M -55 M -3.13 M -768 K -21 M

Interest Expense

-22.4 M -4.68 M -13 K -25 K 32 K 83 K 79 K 59 K -81 K -78 K -23 K

EBITDA

-233 M -221 M -176 M -127 M -135 M -110 M -131 M -54.3 M -2.42 M 79 K -20.5 M

Operating Expenses

- 236 M 201 M 150 M 147 M 120 M 135 M 96.5 M 71.6 M - -

General and Administrative Expenses

134 M 125 M 68.3 M 44 M 37.2 M 28.4 M 23.9 M 20.9 M 14 M 7.51 M 5 M

All numbers in USD currency

Quarterly Income Statement Epizyme

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - 167 K 144 K 106 M 103 M 102 K 102 K 102 M 102 M 101 M 99.6 M 95.1 M 91 M 90.9 M 82.4 M 79 M 69.5 M 69.5 M 69.4 M 69.3 M 59.9 M 58.4 M 58.2 M 58 M 58 M 57.4 M 55.1 M 41.7 M 41.5 M 41.1 M 35 M 34.3 M 33.7 M 33.2 M 31 M 28.4 M 28.4 M 9.15 M 1.79 M 1.67 M 1.65 M 1.64 M 1.62 M - - - -

Net Income

- - -35.7 M -55.5 M - -65.8 M -64.4 M -70.3 M -66.2 M -56.1 M -58.5 M -50.9 M -56.4 M -36.1 M -48.5 M -29.3 M -22.9 M -37.5 M -29.1 M -34.1 M -36.2 M -37.6 M -28 M -32.5 M -35 M -24.3 M -28 M -22.9 M -22.2 M -23.1 M -25.8 M -61.3 M -15 M -19.7 M -13.4 M -6.88 M 15.9 M -9.7 M -2.21 M -7.5 M -4.54 M 4.45 M 4.86 M -5.47 M - - - -

Revenue

- - 27.5 M 8.7 M - 5.2 M 13 M 7.63 M 8.38 M 3.57 M 2.47 M 1.35 M 4.29 M 5.72 M 5.9 M 7.89 M 9.7 M 12 M 12 M - - 10 M 10 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - 5.17 M 2.64 M - 2 M 2.49 M 2.85 M 1.82 M 1.61 M 1.02 M 614 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - -29.8 M -50.9 M - -64.1 M -58.2 M -64.3 M -62.1 M -54.4 M -57.6 M -51.4 M -57.5 M -38 M -50.7 M -31 M -24.3 M -38.6 M -30.3 M -35 M -37.4 M -38.1 M -28.5 M -33 M -35.5 M -24.8 M -28.4 M -23.1 M -22.3 M -23.1 M -25.8 M -61.4 M -15.1 M -19.7 M -13.3 M -6.91 M 16.3 M -9.73 M -2.18 M -7.48 M -4.54 M 4.44 M 4.8 M -5.48 M - - - -

Interest Expense

- - -5.39 M -5.48 M - -5.64 M -5.58 M -5.48 M -3.97 M -1.72 M -885 K 413 K 1.15 M 1.86 M 2.24 M -6 K - -6 K -11 K 18 K - -32 K 10 K 4 K - 21 K - - - - - 20 K - 17 K 12 K 12 K - 3 K -50 K -39 K - -39 K - - - - - -

EBITDA

- - -27.2 M -49.6 M - -63.1 M -55.6 M -63.1 M -62.1 M -51.7 M -56.2 M -50.8 M -57.5 M -37.3 M -50.3 M -30.8 M -24.3 M -37.8 M -29.7 M -34.6 M -37.4 M -36.8 M -27.6 M -32.6 M -35.5 M -23.6 M -27.6 M -22.7 M -22.3 M -22 M -25.1 M -61.1 M -15.1 M -19.2 M -12.9 M -6.74 M 16.3 M -9.19 M -1.81 M -7.3 M -4.54 M 4.88 M 5.1 M -5.48 M - - - -

General and Administrative Expenses

- - 24.1 M 27.2 M - 32.8 M 33.9 M 36.4 M 35 M 30.6 M 32.7 M 26.9 M 23.5 M 17.1 M 15.7 M 12 M 12.2 M 11.5 M 10.9 M 9.36 M 8.43 M 9.31 M 11.2 M 8.27 M 7.58 M 7.52 M 7.42 M 5.85 M 6.02 M 6.68 M 5.97 M 5.24 M 4.94 M 5.67 M 5.31 M 4.96 M 4.38 M 3.59 M 3.08 M 3 M 2.33 M 1.63 M 1.64 M 1.91 M - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Epizyme EPZM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Epizyme plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.72 0.96 % $ 783 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.32 -1.19 % $ 257 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.26 -2.47 % $ 1.22 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 209.93 -0.11 % $ 5 B danmarkDanmark
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.31 -1.88 % $ 7.14 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 -0.71 % $ 8.18 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 89.77 -0.57 % $ 96.9 B britainBritain
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.59 1.05 % $ 141 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Biogen Biogen
BIIB
$ 174.05 0.9 % $ 25.3 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.33 2.08 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.26 -5.4 % $ 505 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.78 -1.28 % $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 570.12 -1.88 % $ 43.2 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.28 -2.76 % $ 609 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.66 -4.25 % $ 965 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
BioVie BioVie
BIVI
$ 1.47 -2.55 % $ 2.17 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.54 -1.43 % $ 1.77 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.61 -4.5 % $ 44.1 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.3 -1.22 % $ 731 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.15 -0.23 % $ 397 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA